- Home
- CYRX vs AUTL Comparison
CYRX vs AUTL Comparison
Compare CYRX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- AUTL
- Stock Information
- Founded
- CYRX 1999
- AUTL 2014
- Country
- CYRX United States
- AUTL United Kingdom
- Employees
- CYRX N/A
- AUTL N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CYRX Health Care
- AUTL Health Care
- Exchange
- CYRX Nasdaq
- AUTL Nasdaq
- Market Cap
- CYRX 438.7M
- AUTL 368.6M
- IPO Year
- CYRX N/A
- AUTL 2018
- Fundamental
- Price
- CYRX $8.80
- AUTL $1.24
- Analyst Decision
- CYRX Strong Buy
- AUTL Strong Buy
- Analyst Count
- CYRX 9
- AUTL 3
- Target Price
- CYRX $12.83
- AUTL $8.33
- AVG Volume (30 Days)
- CYRX 722.5K
- AUTL 2.4M
- Earning Date
- CYRX 11-04-2025
- AUTL 11-12-2025
- Dividend Yield
- CYRX N/A
- AUTL N/A
- EPS Growth
- CYRX N/A
- AUTL N/A
- EPS
- CYRX 1.27
- AUTL N/A
- Revenue
- CYRX $243,795,000.00
- AUTL $51,128,000.00
- Revenue This Year
- CYRX N/A
- AUTL $643.50
- Revenue Next Year
- CYRX $9.20
- AUTL $108.69
- P/E Ratio
- CYRX $6.95
- AUTL N/A
- Revenue Growth
- CYRX 41.27
- AUTL 406.67
- 52 Week Low
- CYRX $4.58
- AUTL $1.11
- 52 Week High
- CYRX $11.44
- AUTL $3.45
- Technical
- Relative Strength Index (RSI)
- CYRX 46.95
- AUTL 37.67
- Support Level
- CYRX $8.15
- AUTL $1.25
- Resistance Level
- CYRX $9.29
- AUTL $1.35
- Average True Range (ATR)
- CYRX 0.49
- AUTL 0.10
- MACD
- CYRX -0.02
- AUTL -0.01
- Stochastic Oscillator
- CYRX 43.54
- AUTL 7.46
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.